Bringing value to cancer research
This article argues for incorporating a broader definition of “value” into cancer clinical trials. Current trials primarily focus on efficacy and safety, neglecting patient-reported outcomes (PROs) such as quality of life, financial toxicity, and time burden, as well as cost-effectiveness. We propos...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1580575/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321547677827072 |
|---|---|
| author | Casey J. Allen Horn M. Danea Fabrice Smieliauskas Stephen Edge Rachel A. Greenup |
| author_facet | Casey J. Allen Horn M. Danea Fabrice Smieliauskas Stephen Edge Rachel A. Greenup |
| author_sort | Casey J. Allen |
| collection | DOAJ |
| description | This article argues for incorporating a broader definition of “value” into cancer clinical trials. Current trials primarily focus on efficacy and safety, neglecting patient-reported outcomes (PROs) such as quality of life, financial toxicity, and time burden, as well as cost-effectiveness. We propose a novel framework integrating oncologic outcomes, PROs, and cost analyses. We also propose a multidimensional visual tool, such as a radar chart, to facilitate better-informed, value-based shared decision-making. This requires a collaborative approach, involving stakeholders in defining value metrics. While acknowledging challenges such as increased administrative burden and data interpretation complexities, a comprehensive framework can substantially improve patient-centered cancer care. The ultimate goal is to standardize value assessment in cancer research, leading to more equitable and effective care. |
| format | Article |
| id | doaj-art-5cf7ab52c86d4a35995300f48dc2e11e |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-5cf7ab52c86d4a35995300f48dc2e11e2025-08-20T03:49:42ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-05-011510.3389/fonc.2025.15805751580575Bringing value to cancer researchCasey J. Allen0Horn M. Danea1Fabrice Smieliauskas2Stephen Edge3Rachel A. Greenup4Division of Surgical Oncology, Institute of Surgery, Allegheny Health Network, Pittsburgh, PA, United StatesSchool of Pharmacy, University of California, San Francisco, San Francisco, CA, United StatesDepartment of Economics and Department of Pharmacy Practice, Wayne State University, Detroit, MI, United StatesRoswell Park Comprehensive Cancer Center and Jacobs School of Medicine, University at Buffalo, Buffalo, NY, United StatesDepartment of Surgery and Smilow Cancer Hospital, Yale School of Medicine, New Haven, CT, United StatesThis article argues for incorporating a broader definition of “value” into cancer clinical trials. Current trials primarily focus on efficacy and safety, neglecting patient-reported outcomes (PROs) such as quality of life, financial toxicity, and time burden, as well as cost-effectiveness. We propose a novel framework integrating oncologic outcomes, PROs, and cost analyses. We also propose a multidimensional visual tool, such as a radar chart, to facilitate better-informed, value-based shared decision-making. This requires a collaborative approach, involving stakeholders in defining value metrics. While acknowledging challenges such as increased administrative burden and data interpretation complexities, a comprehensive framework can substantially improve patient-centered cancer care. The ultimate goal is to standardize value assessment in cancer research, leading to more equitable and effective care.https://www.frontiersin.org/articles/10.3389/fonc.2025.1580575/fullqualitycostshared decision-makinggoal-concordant careclinical trials |
| spellingShingle | Casey J. Allen Horn M. Danea Fabrice Smieliauskas Stephen Edge Rachel A. Greenup Bringing value to cancer research Frontiers in Oncology quality cost shared decision-making goal-concordant care clinical trials |
| title | Bringing value to cancer research |
| title_full | Bringing value to cancer research |
| title_fullStr | Bringing value to cancer research |
| title_full_unstemmed | Bringing value to cancer research |
| title_short | Bringing value to cancer research |
| title_sort | bringing value to cancer research |
| topic | quality cost shared decision-making goal-concordant care clinical trials |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1580575/full |
| work_keys_str_mv | AT caseyjallen bringingvaluetocancerresearch AT hornmdanea bringingvaluetocancerresearch AT fabricesmieliauskas bringingvaluetocancerresearch AT stephenedge bringingvaluetocancerresearch AT rachelagreenup bringingvaluetocancerresearch |